A Response to: Letter to the Editor Regarding “Tafamidis 61 mg Patient Characteristics and Persistency? A Retrospective Analysis of German Statutory Health Insurance Data (IQVIA™ LRx)”
本文未提供摘要，请点击“查看全文”查看完整内容。